UroGen Pharma’s (URGN) “Buy” Rating Reaffirmed at D. Boral Capital

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $25.00 target price on the stock. D. Boral Capital’s price target would indicate a potential upside of 148.76% from the company’s current price.

Several other analysts also recently weighed in on URGN. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of UroGen Pharma in a report on Tuesday, October 15th. Finally, Oppenheimer reissued an “outperform” rating and set a $40.00 price objective on shares of UroGen Pharma in a report on Wednesday, October 16th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $43.70.

UroGen Pharma Trading Down 1.4 %

Shares of UroGen Pharma stock opened at $10.05 on Thursday. The company has a market capitalization of $235.67 million, a P/E ratio of -3.19 and a beta of 1.09. The company’s fifty day moving average is $11.30 and its two-hundred day moving average is $13.03. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma has a 1 year low of $9.78 and a 1 year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to analysts’ expectations of $24.22 million. During the same period in the previous year, the firm earned ($0.68) EPS. Analysts forecast that UroGen Pharma will post -3.1 earnings per share for the current year.

Hedge Funds Weigh In On UroGen Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its position in UroGen Pharma by 44.1% during the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock worth $216,000 after acquiring an additional 6,207 shares during the last quarter. JPMorgan Chase & Co. raised its position in UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock worth $864,000 after acquiring an additional 49,318 shares during the last quarter. Tidal Investments LLC raised its position in UroGen Pharma by 19.1% during the third quarter. Tidal Investments LLC now owns 37,595 shares of the company’s stock worth $477,000 after acquiring an additional 6,030 shares during the last quarter. Barclays PLC raised its position in UroGen Pharma by 409.3% during the third quarter. Barclays PLC now owns 59,778 shares of the company’s stock worth $759,000 after acquiring an additional 48,040 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in UroGen Pharma by 8.1% during the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock worth $5,787,000 after acquiring an additional 34,248 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.